Last edition
News about "Satish Mehta"
Emcure Launches Poviztra to Broaden Access to Weight Management Therapy
Emcure has launched Poviztra, a once-weekly weight management therapy available in a pen device across five dosage strengths, with prices starting at INR 8,790 per month, aimed at improving access through convenient and precise dosing.
Satish Mehta | 22/12/2025 | By News Bureau
Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra in India
Under this agreement, Emcure becomes the first Indian company to hold exclusive rights for the distribution and commercialisation of the drug, expanding access to Novo Nordisk’s innovative semaglutide therapy for people living with overweight and obesity in the country.
Satish Mehta | 10/11/2025 | By Dineshwori | 275
Sanofi India, Emcure Sign Exclusive Distribution Partnership for Anti-Diabetic Drugs
Sanofi India Ltd. has entered into an exclusive distribution and promotion agreement with Emcure Pharmaceuticals for its oral anti-diabetic brands, including Amaryl and Cetapin, aiming to expand patient access and strengthen diabetes care across India.
Satish Mehta | 17/07/2025 | By Mrinmoy Dey | 239
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy